In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae
- PMID: 12917246
- DOI: 10.1093/jac/dkg371
In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae
Abstract
Objectives: To investigate the in vitro activity of cethromycin, a new ketolide, against Chlamydia pneumoniae.
Methods: The in vitro activity of cethromycin against 20 isolates of C. pneumoniae was compared with the activities of telithromycin, erythromycin A, azithromycin and clarithromycin against those isolates.
Results: The MIC at which 90% of the isolates were inhibited and the minimal chlamydiacidal concentration at which 90% of the isolates were killed by cethromycin were both 0.016 mg/L (range 0.016-0.031 mg/L). Cethromycin was the most active antibiotic tested in this study.
Conclusions: Our results appear to indicate that cethromycin is an effective antibiotic that should play some role in the treatment of respiratory tract infections caused by C. pneumoniae.
Similar articles
-
In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae.J Antimicrob Chemother. 2001 Sep;48(3):403-5. doi: 10.1093/jac/48.3.403. J Antimicrob Chemother. 2001. PMID: 11533006
-
Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.J Antimicrob Chemother. 2003 Apr;51(4):1025-8. doi: 10.1093/jac/dkg154. Epub 2003 Feb 25. J Antimicrob Chemother. 2003. PMID: 12654764 Clinical Trial.
-
In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.Antimicrob Agents Chemother. 2000 Apr;44(4):1112-3. doi: 10.1128/AAC.44.4.1112-1113.2000. Antimicrob Agents Chemother. 2000. PMID: 10722526 Free PMC article.
-
Cethromycin: a promising new ketolide antibiotic for respiratory infections.Pharmacotherapy. 2010 Mar;30(3):290-303. doi: 10.1592/phco.30.3.290. Pharmacotherapy. 2010. PMID: 20180612 Review.
-
Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.Expert Opin Investig Drugs. 2008 Mar;17(3):387-400. doi: 10.1517/13543784.17.3.387. Expert Opin Investig Drugs. 2008. PMID: 18321237 Review.
Cited by
-
Carbohydrate-based drugs launched during 2000-2021.Acta Pharm Sin B. 2022 Oct;12(10):3783-3821. doi: 10.1016/j.apsb.2022.05.020. Epub 2022 May 23. Acta Pharm Sin B. 2022. PMID: 36213536 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical